Background: This study analyzes patient health-related quality of life (QoL) 24-month after prostate cancer (PCa) diagnosis within the PROState cancer monitoring in ITaly from the National Research Council (Pros-IT CNR) study. Methods: Pros-IT CNR is an ongoing, longitudinal and observational study, considering a convenience sample of patients enrolled at PCa diagnosis and followed at 6, 12, 24, 36, 48 and 60 months from the diagnosis. Patients were grouped according to the treatment received: nerve sparing radical prostatectomy (NSRP), non-nerve sparing radical prostatectomy (NNSRP), radiotherapy (RT), RT plus androgen deprivation (RT plus ADT) and active surveillance (AS). QoL was measured through the Italian versions of SF-12 and UCLA-PCI questionnaires at diagnosis and at 6-12 and 24-month. The minimal clinically important difference (MCID) was defined as half a standard deviation of the baseline domain. Results: Overall, 1537 patients were included in the study. The decline in urinary function exceeded the MCID at each timepoint only in the NSRP and NNSRP groups (at 24 months -14.7, P<0.001 and -19.7, P<0.001, respectively). The decline in bowel function exceeded the MCID only in the RT (-9.1, P=0.02) and RT plus ADT groups at 12 months (-10.3, P=0.001); after 24 months, most patients seem to recover their bowel complaints. The decline in sexual function exceeded the MCID at each timepoint in the NNSRP, NSRP and RT plus ADT groups (at 6 months -28.7, P<0.001, -37.8, P<0.001, -20.4, P<0.001, respectively). Conclusions: Although all the treatments were relatively well-tolerated over the 24 month period following PCa diagnosis, each had a different impact on QoL.

Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study / Palumbo, Carlotta; Bruni, Alessio; Antonelli, Alessandro; Artibani, Walter; Bassi, Pierfrancesco; Bertoni, Filippo; Borghetti, Paolo; Bracarda, Sergio; Cicchetti, Alessandro; Corvò, Renzo; Gacci, Mauro; Ingrosso, Gianluca; Magrini, Stefano M; Maruzzo, Marco; Mirone, Vincenzo; Montironi, Rodolfo; Muto, Giovanni; Noale, Marianna; Porreca, Angelo; Russi, Elvio; Triggiani, Luca; Tubaro, Andrea; Valdagni, Riccardo; Maggi, Stefania; Conti, Giario N; ProsIT Group CNR, ; Sciarra, Alessandro; Gentilucci, Alessandro. - In: MINERVA UROLOGY AND NEPHROLOGY. - ISSN 2724-6051. - 74:1(2022), p. 11-20. [10.23736/S2724-6051.20.04032-1]

Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study

Antonelli, Alessandro;Russi, Elvio;Tubaro, Andrea;Alessandro, Sciarra;Alessandro, Gentilucci
2022

Abstract

Background: This study analyzes patient health-related quality of life (QoL) 24-month after prostate cancer (PCa) diagnosis within the PROState cancer monitoring in ITaly from the National Research Council (Pros-IT CNR) study. Methods: Pros-IT CNR is an ongoing, longitudinal and observational study, considering a convenience sample of patients enrolled at PCa diagnosis and followed at 6, 12, 24, 36, 48 and 60 months from the diagnosis. Patients were grouped according to the treatment received: nerve sparing radical prostatectomy (NSRP), non-nerve sparing radical prostatectomy (NNSRP), radiotherapy (RT), RT plus androgen deprivation (RT plus ADT) and active surveillance (AS). QoL was measured through the Italian versions of SF-12 and UCLA-PCI questionnaires at diagnosis and at 6-12 and 24-month. The minimal clinically important difference (MCID) was defined as half a standard deviation of the baseline domain. Results: Overall, 1537 patients were included in the study. The decline in urinary function exceeded the MCID at each timepoint only in the NSRP and NNSRP groups (at 24 months -14.7, P<0.001 and -19.7, P<0.001, respectively). The decline in bowel function exceeded the MCID only in the RT (-9.1, P=0.02) and RT plus ADT groups at 12 months (-10.3, P=0.001); after 24 months, most patients seem to recover their bowel complaints. The decline in sexual function exceeded the MCID at each timepoint in the NNSRP, NSRP and RT plus ADT groups (at 6 months -28.7, P<0.001, -37.8, P<0.001, -20.4, P<0.001, respectively). Conclusions: Although all the treatments were relatively well-tolerated over the 24 month period following PCa diagnosis, each had a different impact on QoL.
2022
Androgen Antagonists; Humans; Male; Prostatectomy; Quality of Life; Percutaneous Coronary Intervention; Prostatic Neoplasms
01 Pubblicazione su rivista::01a Articolo in rivista
Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study / Palumbo, Carlotta; Bruni, Alessio; Antonelli, Alessandro; Artibani, Walter; Bassi, Pierfrancesco; Bertoni, Filippo; Borghetti, Paolo; Bracarda, Sergio; Cicchetti, Alessandro; Corvò, Renzo; Gacci, Mauro; Ingrosso, Gianluca; Magrini, Stefano M; Maruzzo, Marco; Mirone, Vincenzo; Montironi, Rodolfo; Muto, Giovanni; Noale, Marianna; Porreca, Angelo; Russi, Elvio; Triggiani, Luca; Tubaro, Andrea; Valdagni, Riccardo; Maggi, Stefania; Conti, Giario N; ProsIT Group CNR, ; Sciarra, Alessandro; Gentilucci, Alessandro. - In: MINERVA UROLOGY AND NEPHROLOGY. - ISSN 2724-6051. - 74:1(2022), p. 11-20. [10.23736/S2724-6051.20.04032-1]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1623104
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact